What is HC Wainwright’s Estimate for ELTX Q2 Earnings?

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – HC Wainwright decreased their Q2 2026 earnings estimates for Elicio Therapeutics in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.46) per share for the quarter, down from their previous forecast of ($0.43). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.87) EPS.

Elicio Therapeutics (NASDAQ:ELTX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.16).

Several other equities research analysts have also weighed in on ELTX. Wall Street Zen lowered shares of Elicio Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Friday, April 24th. Rodman & Renshaw raised shares of Elicio Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Finally, LADENBURG THALM/SH SH started coverage on shares of Elicio Therapeutics in a research report on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Elicio Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Elicio Therapeutics Stock Performance

ELTX opened at $11.44 on Monday. The firm’s fifty day moving average is $10.86 and its two-hundred day moving average is $9.63. The company has a debt-to-equity ratio of 5.75, a quick ratio of 2.24 and a current ratio of 2.24. The firm has a market cap of $218.39 million, a PE ratio of -4.77 and a beta of 1.13. Elicio Therapeutics has a twelve month low of $6.90 and a twelve month high of $14.93.

Institutional Investors Weigh In On Elicio Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ELTX. Susquehanna International Group LLP raised its position in shares of Elicio Therapeutics by 606.1% in the 3rd quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock valued at $1,315,000 after buying an additional 103,184 shares in the last quarter. Renaissance Technologies LLC increased its position in Elicio Therapeutics by 332.7% in the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock valued at $1,300,000 after acquiring an additional 93,520 shares during the period. 683 Capital Management LLC acquired a new position in Elicio Therapeutics in the 4th quarter valued at approximately $449,000. Geode Capital Management LLC increased its position in Elicio Therapeutics by 56.0% in the 2nd quarter. Geode Capital Management LLC now owns 120,831 shares of the company’s stock valued at $933,000 after acquiring an additional 43,364 shares during the period. Finally, Royal Bank of Canada acquired a new position in Elicio Therapeutics in the 1st quarter valued at approximately $225,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.